N
6-(2-Deoxy-d-erythro-pentofuranosyl)-2,6-diamino-3,4-dihydro-4-oxo-5-N-methylformamidopyrimidine (MeFapy-dGuo) has been identified
as a
stable DNA adduct that arises from the reaction of DNA with a variety
of methylating agents. Since this lesion persists in DNA and may contribute
to the overall mutagenesis from electrophilic methylating agents,
the MeFapy-dGuo lesion was incorporated into oligonucleotides, and
its replication bypass was examined in vitro with a panel of eukaryotic
high fidelity (hPols α, β, and δ/PCNA) and translesion
(hPols η, κ, ι, Rev1, ν, and yPol ζ)
polymerases to address its miscoding potential. The MeFapy-dGuo was
found to be a strong block to the high fidelity polymerases at either
the insertion or the extension step. Efficient translesion synthesis
was observed for hPols η and κ, and the combined activities
of hRev1 and yPol ζ. The nucleotide sequences of the extension
products were determined by mass spectrometry. The error-free extension
product was the most abundant product observed for each polymerase.
Misreplication products, which included misinsertion of Thy, Gua,
and Ade opposite the MeFapy-dGuo lesion, as well as an interesting
one-nucleotide deletion product, were observed when hPols η
and κ were employed; these events accounted for 8–29%
of the total extension products observed. The distribution and abundance
of the misreplication products were dependent on the polymerases and
local sequence context of the lesion. Collectively, these data suggest
that although MeFapy-dGuo adducts represent a relatively minor proportion
of the total alkylated lesions, their miscoding potentials could significantly
contribute to genomic instability.